Chronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma. Until recently the treatment with the available drugs yielded a viral response in only 45–70% of patients with a high incidence of disease recurrence. Also the present medication is not well tolerated by patients. The new drug promises a response rate of more than 90% with few side effects.
